137.64 USD
↘ 0.91 (0.66%)AT CLOSE (11:59 AM EDT)
Gilead Sciences Inc
GILDNASDAQ • USD
137.95
↗ 0.31 (0.23%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
137.95
↗ 0.31 (0.23%)
Market: CLOSED
Open?$138.95
High?$139.76
Low?$136.69
Prev. Close?$138.55
Volume?7.3M
Avg. Volume?5.7M
VWAP?$137.91
Rel. Volume?1.28x
Bid / Ask
Bid?$131.57 × 100
Ask?$145.94 × 100
Spread?$14.37
Midpoint?$138.76
Valuation & Ratios
Market Cap?170.8B
Shares Out?1.2B
Float?1.2B
Float %?99.7%
P/E Ratio?20.08
P/B Ratio?7.53
EPS?$6.86
Dividend?2.34%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.55Adequate
Quick Ratio?1.40Adequate
Cash Ratio?0.64Adequate
Debt/Equity?1.10Moderate
ValuationFAIRLY VALUED
Score67/100
P/E?20.1FAIR▾
P/B?7.53FAIR▾
P/S?5.80FAIR▾
P/FCF?18.1CHEAP▾
EV/EBITDA?13.1FAIR▾
EV/Sales?6.39HIGH▾
Returns & Efficiency
ROE?37.5%STRONG▾
ROA?14.4%STRONG▾
Cash Flow & Enterprise
FCF?$9.5B
Enterprise Value?$188.2B
Related Companies
News
Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees
17.0K
Market Cap
170.8B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1992-01-22
Address
333 LAKESIDE DR
FOSTER CITY, CA 94404
Phone: (650) 574-3000
FOSTER CITY, CA 94404
Phone: (650) 574-3000